PCM
PBYI icon

Prelude Capital Management’s Puma Biotechnology PBYI Stock Holding History

Prelude Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-300
Closed -$72K – 2102
2014
Q3 		$72K Sell
300
-500
-63% -$103K 0.01% 1244
2014
Q2 		$53K Buy
+800
New +$56.9K 0.01% 1342

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prelude Capital Management's PBYI Position: Q2 2026 in Review

Prelude Capital Management increased its Puma Biotechnology (PBYI) stake by 17% in Q2 2026, buying an estimated $22.7K and bringing the position to 21,548 shares worth $175K. The position accounts for 0.01% of the portfolio, ranked #1010.

Prelude Capital Management first reported a position in PBYI in Q1 2015 and has held it in 15 quarters since. The position peaked at $1.22M in Q4 2017. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Prelude Capital Management held 21,548 shares of Puma Biotechnology worth $175K as of Q2 2026.
  • Prelude Capital Management bought 3,100 Puma Biotechnology shares in Q2 2026, an estimated $22.7K.
  • Puma Biotechnology made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1010 holding.
  • Prelude Capital Management first reported a position in Puma Biotechnology in Q1 2015 and has held it in 15 quarters since.
  • Prelude Capital Management's Puma Biotechnology position peaked at $1.22M in Q4 2017.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.